Is bevacizumab a hormonal drug?

Bevacizumab (Bevacizumab) is not a hormonal drug. It is an anti-angiogenic recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) and is mainly used to inhibit the formation of new blood vessels in tumors.

In terms of pharmacological mechanism, it is essentially different from hormonal drugs. Hormone drugs are usually derived from the endocrine system, such as adrenocortical hormones or sex hormones, acting on endogenous hormone pathways to regulate systemic metabolism, immunity or inflammatory responses. As a targeted therapy drug, bevacizumab mainly acts on specific molecular targets in the peripheral circulation and does not participate in the regulation of hormone levels or endocrine metabolism.

Its function is more focused on molecularly precise attacks on tumor-dependent angiogenesis signals, reducing tumor nutrient supply, thereby slowing down tumor volume expansion. Clinically, bevacizumab is widely used to treat solid tumors such as non-small cell lung cancer, advanced colorectal cancer, cervical cancer, ovarian cancer, and renal cell carcinoma, usually as part of a combination treatment regimen. Although hormonal drugs such as prednisone or tamoxifen can also be used to treat some tumors, their therapeutic mechanisms are mainly immunosuppression or hormone receptor regulation and do not involve tumor angiogenesis mechanisms.

It is worth noting that although bevacizumab is not a hormonal drug, its adverse reactions may include hypertension, proteinuria, or bleeding tendencies. These side effects are not caused by hormonal imbalance. In summary, bevacizumab is a non-hormonal targeted anti-cancer drug. Its bioengineering background and mechanism of action indicate that it belongs to the modern molecular targeted therapy system and has no overlap with traditional hormonal drugs in classification. Patients do not need to worry about hormone-related side effects while receiving this drug, but they should still be closely monitored for individual tolerability and vascular-related reactions to the drug.

Reference materials:https://www.drugs.com/bevacizumab.html